ClinicalTrials.gg

Hidradenitis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 34 studies for Hidradenitis across more than 10 countries. 9 are recruiting or about to start. 5 of them are mainly about Hidradenitis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Hidradenitis Suppurativa too: 292 studies, 89 open.

Status

Completed
13
Recruiting
8
Active, not recruiting
5
Status unknown
4
Terminated
3
Enrolling by invitation
1

Phase

Phase 2
11
Phase 3
10
Phase 1
2

Where

United States
25
Canada
15
Poland
14
Germany
13
Spain
12
France
9

Who develops what

Add Hidradenitis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 8 programs from 7 companies, 2 with this as their studies’ main aim; 3 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Sanofi, Almirall and Incyte here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
bimekizumabRecent, limited
Evidence
  • NCT07766005 · Spyre Therapeutics, Inc. · Phase 2 · live · background · “bimekizumab” · registered Aug 2026
UCB S.A.100% of its industry studiesUS: UCB S.A. (FDA 2023)EU: UCB S.A. (EMA 2021)11 study
AdalimumabRecent, limited
Evidence
  • NCT05322473 · MoonLake Immunotherapeutics AG · Phase 2 · comparator · “Adalimumab” · registered Apr 2022
Abbott41% of its industry studiesUS: Amgen (FDA 2016) + 3 othersEU: AbbVie (EMA 2003) + 10 others11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 8 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 26 Dec 2026 est.povorcitinib · Incyte Corporation · Phase 3 named, not the main aimNCT06212999 A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa — primary endpoint: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs) · 617 enrolled
  • Feb 2027 est.LAD328 · Almirall, S.A. · Phase 2 named, not the main aimNCT07547813 A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa — primary endpoint: Proportion of Participants Achieving 55 Percent (%) Reduction from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4-55) · 50 enrolled
  • 17 May 2027 est.remibrutinib · Novartis · Phase 3 named, not the main aimNCT06799000 A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) — primary endpoint: Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50) at Week 16 · 588 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hidradenitis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open

Coming up

5studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 5, phase 3 first

Who these studies take

Of the 8 Hidradenitis studies recruiting now, 4 (50%) set no upper age limit and 4 (50%) stop at 75 or younger. 2 (25%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.

Recruiting studies that take each age, of 8
AgeWomenMen
101 (13%)1 (13%)
187 (88%)7 (88%)
307 (88%)7 (88%)
407 (88%)7 (88%)
507 (88%)7 (88%)
657 (88%)7 (88%)
755 (63%)5 (63%)
854 (50%)4 (50%)

Across all 34 studies, recruiting or not: 26% stop at 75 or younger and 15% at 65; 24% take children; 3% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 34 of 34. search them.